RxDoctor Payments Data

Andrea Keller

Physician Assistant · Fairfax, VANPI 1740594928

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $23,490 of the $37,031 with a category attached, or 63.4%. Gilead accounts for 98.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $15,152 and has fallen 52.4% since, to $7,212 in 2025. Among physician assistant clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$37,031in general payments, 2019–2025

Across 111 payments — averaging $333.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$36K
  • GSK$250
  • Intercept Pharmaceuticals, Inc.$130
  • AbbVie$103
  • Ipsen Biopharmaceuticals, Inc$46
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$41
  • plus $41 from 1 others

What the payments were for

  • Consulting fees$9503%
  • Speaking & faculty fees$23,49063%
  • Travel & lodging$10,42328%
  • Food & beverage$2,1686%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,031 in reported general payments places this provider in the 95th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$31,423
Medicare patients
159
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide154$246,290
XifaxanRifaximin57$214,261
Ursodiol69$19,147
LokelmaSodium Zirconium Cyclosilicate11$8,890
Tacrolimus94$7,741
Tenofovir Disoproxil Fumarate47$4,855
Entecavir22$4,059
Azathioprine24$3,671
Mycophenolate Mofetil27$2,882
Lactulose18$1,194
Spironolactone43$1,074
Pantoprazole Sodium47$568
Propranolol Hcl16$370
Omeprazole27$334
Ondansetron Hcl15$309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$36,421$246,290154 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$41$214,26157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →